In the Spotlight
An Information Prescription for Drug Regulation
Joseph Bernstein, MD, FACS, Anita Bernstein, JD, Medical Progress Today, 8-31-07
Americans reading about the sorry state of drug regulation in China—an unhappy mixture of ineptitude and corruption—can be forgiven their sense of superiority. Flawed though it may be, the FDA has managed to keep antifreeze out of our medicines for the last 70 years and none of its administrators now awaits the death penalty. Still, we are not entitled to complacency. It's clear that some dangerous and ineffective drugs have garnered FDA approval. Less well known, yet perhaps more costly overall, is that in the name of promoting safety, some potentially beneficial drugs have been denied access to the market as well.
Continue reading . . .
· Medical Device Recalls and the FDA Approval Process, Zuckerman, D. M., Brown, P., Nissen, S. E., Archives of Internal Medicine, 6-14-11
· Patent Reform Gets Key Support in House, Julian Pecquet, The Hill, 6-14-11
· $4.3 Billion Pledged at Vaccine Fund-Raiser, Donald G. McNeil Jr., New York Times, 6-13-2011
· Physicians Leaving Practices for health System Employment, Karen Cheung, FierceHealthcare, 6-13-11
More Headlines >>
Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.
For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at email@example.com, or via telephone at 212.599.7000.
Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at firstname.lastname@example.org, or via telephone at 212.599.7000.
If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.